14-November-2026:
The Union Health Ministry’s 4 November proposal would allow immediate suspension of manufacturing licences in respect of products that fail specified critical quality tests. These include assay, dissolution, impurities and sterility. The draft also proposes that restoration follow verification of the manufacturer’s corrective and preventive measures. India’s drug regulators should use this opportunity to shorten the time between a confirmed test failure and action across the supply chain.
Production can stop while stock from an affected batch is still with a distributor, on a pharmacy shelf or in a hospital storeroom. A pharmacist needs the exact batch number, product strength and instructions for handling existing stock. A hospital needs to know whether its suppliers have sent the affected lots and whether it can source alternatives. When notices arrive in different formats or through different channels, each institution spends time reconstructing the same information.
The Central Drugs Standard Control Organisation and state regulators should adopt a standard electronic notice with product and batch identifiers, the affected geography where known and a contact for follow-up. Manufacturers and distributors should be able to account for stock dispatched, quarantined and recovered. In a shortage-sensitive category, hospitals and procurement agencies also need early notice to plan alternative supply.
Regulators should publish the elapsed time from confirmed failure to notice, and from notice to verification of action in the field. A fast licensing decision can reduce exposure. Its impact depends on how quickly the information reaches the people dispensing the medicine.
